Redwood City's Jasper Therapeutics, the once high-flying biotech firm with a peak valuation upwards of $320 million, has plummeted to a sobering $53 million after blunders in the development of its lead drug, briquilimab, effectively derailed clinical trials and precipitated a mass layoff. SFGATE reports that issues with a batch of the drug used in studies for chronic hives and asthma have led to a workforce reduction of about 50%, striking a chord of uncertainty for Jasper's future.
Specifically addressing these operational mishaps, CEO Ronald Martell stated to SFGATE that "While it is very difficult to part with so many talented and valued members of our team, we view this as a necessary step to ensure we closely manage our capital to execute on our mission to deliver a differentiated therapeutics option to patients in need." Jasper is ceasing its research into asthma and severe combined immunodeficiency disorder as part of the company's slimming measures. It is funneling its resources into chronic hives treatment alone, now with a leaner team and a clearer but challenging path ahead.
In a recent announcement from Jasper, it was confirmed that the company's Chief Medical Officer, Edwin Tucker, M.D., will be departing, and his role will be subsequently filled by Daniel Adelman, M.D., previously a member of Jasper's Scientific Advisory Board. Adelman brings extensive experience in clinical development within the biopharma industry, having worked on key projects, including developing therapies for celiac disease and food allergies, perhaps signaling a strategic pivot as Jasper re-aligns its focus exclusively on chronic urticaria.
